Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Companyâs lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe. In addition, the Company is developing Fexapotide for early-stage, non-aggressive prostate cancer (PCA). There is a significant unmet clinical need in this patient population of elderly men. FT has completed a phase II trial in the United States in 147 men demonstrating important long-term (up to 5 year) clinical benefits in men receiving FT, including significant delay in disease progression compared to controls. The Company is headquartered in Nassau, Bahamas, and has office locations in Canada, the United States and Switzerland. The Company is in the process of relocating its headquarters from the Bahamas to Switzerland. Source
No articles found.
Novartis is reimagining medicine to improve and extend peoples lives. As a leadin...
Novartis is reimagining medicine to improve and...
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...
ImmunoGen is developing the next generation of ...
Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet...
Theratechnologies (TSX: TH) is a specialty phar...
Osmotica Pharmaceuticals plc is a fully-integrated biopharmaceutical company focus...
Osmotica Pharmaceuticals plc is a fully-integra...
Voyager Therapeutics is developing life-changing gene therapies for fatal and debi...
Voyager Therapeutics is developing life-changin...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Viveve, Inc., the wholly owned subsidiary of Viveve Medical, Inc., is a women's in...
Viveve, Inc., the wholly owned subsidiary of Vi...
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company foc...
Founded in November 2012, ObsEva is a clinical-...
Join the National Investor Network and get the latest information with your interests in mind.